Edmund K. Waller
Expertise in
27
conditions

Dr. Edmund K. Waller

Hematology Oncology
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
41 Years of Experience
Referral may be required
Expertise in
27
conditions
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 

Overview

Edmund Waller is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 41 years.

Dr. Waller is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

Dr. Waller is board certified in American Board Of Internal Medicine, 1991. He is actively involved in clinical research, co-authoring 283 peer reviewed articles and participating in 9 clinical trials.

Graduate Institution

Cornell Univ Medical College, 1985.0

Residency

Stanford University Hospital

Specialties

Hematology Oncology

Licenses

Internal Medicine in GA

Board Certifications

American Board Of Internal Medicine, 1991

Fellowships

Stanford University Hospital

Hospital Affiliations

Emory University Hospital Midtown
Emory University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Diffuse Large B Cell Lymphoma (DEEP T CELLS)
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Diffuse Large B Cell Lymphoma (DEEP T CELLS)
Enrollment Status: Completed
Publish Date: January 20, 2025
Intervention Type: Drug, Biological
Study Drugs: Duvelisib, Tisagenlecleucel
Study Phase: Early Phase 1
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
Enrollment Status: Completed
Publish Date: April 04, 2024
Intervention Type: Drug, Procedure
Study Drugs: Tacrolimus, Methotrexate, Mycophenolate Mofetil, Cyclophosphamide
Study Phase: Phase 3
Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Drug
Study Drug: Itacitinib
Study Phase: Phase 2
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Biological
Study Drug: Neihulizumab (AbGn-168H)
Study Phase: Phase 1
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: October 21, 2022
Intervention Type: Drug
Study Drugs: Natalizumab, Steroids
Study Phase: Phase 2
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Enrollment Status: Completed
Publish Date: August 15, 2022
Intervention Type: Drug, Biological
Study Drugs: Tisagenlecleucel, Pembrolizumab
Study Phase: Phase 1
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
Enrollment Status: Withdrawn
Publish Date: November 07, 2018
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

283 Total Publications

Dysbiosis and gastrointestinal GVHD: to treat or not to treat.
Dysbiosis and gastrointestinal GVHD: to treat or not to treat.
Journal: Blood
Published: February 19, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Jonathon B. Cohen
Hematology Oncology
Expertise in
26
conditions
Dr. Jonathon B. Cohen
Hematology Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-1900
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathon Cohen is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 19 years. Dr. Cohen is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Vitrectomy. Dr. Cohen is board certified in American Board Of Internal Medicine, 2014.

Expertise in
20
conditions
Dr. Kristie A. Blum
Hematology Oncology
Expertise in
20
conditions
Dr. Kristie A. Blum
Hematology Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-1900
Experience:
29+ years
Languages Spoken:
English
See accepted insurances

Kristie Blum is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 29 years. Dr. Blum is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Blum is board certified in American Board Of Internal Medicine, 2004.

Expertise in
16
conditions
Dr. Sagar Lonial
Hematology Oncology
Expertise in
16
conditions
Dr. Sagar Lonial
Hematology Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-0519
Experience:
33+ years
Languages Spoken:
English
See accepted insurances

Sagar Lonial is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 33 years. Dr. Lonial is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Aplastic Anemia, and Bone Marrow Transplant. Dr. Lonial is board certified in American Board Of Internal Medicine, 2000.

Frequently Asked Questions about Dr. Edmund K. Waller

How do I make an appointment with Dr. Edmund K. Waller?

You can book an appointment with Dr. Edmund K. Waller by calling their office at 404-778-0519. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Edmund K. Waller a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Edmund K. Waller is classified as an Elite expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Edmund K. Waller specialize in?

While Dr. Edmund K. Waller is a Hematology Oncology, they have specific expertise in Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Edmund K. Waller participate in research or clinical trials?

Yes. Dr. Edmund K. Waller has published 283 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Dr. Edmund K. Waller's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Edmund K. Waller accept my insurance?

Dr. Edmund K. Waller accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 404-778-0519 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Waller's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile